Zika Virus
Conditions
Keywords
Zika virus, Vaccine
Brief summary
This is a phase 1 double-blind, placebo controlled trial designed to evaluate the safety, reactogenicity, and immunogenicity of a single dose of the live attenuated Zika vaccine rZIKV/D4Δ30-713 in adults with no history of previous flavivirus infection.
Detailed description
Fifty-six healthy volunteers will be enrolled over 2 sequential cohorts: Cohort 1: n=28, volunteers will be randomly assigned to a single dose of either vaccine (10\^3 PFU, n=20) or placebo (n=8). Cohort 1 will be enrolled and evaluated first. If the vaccine is not found to induce seroconversion to ZIKV in \> 80% of subjects inoculated with 10-\^3 PFU of the vaccine, a second cohort of volunteers will be enrolled and will be inoculated with 10\^4 PFU of vaccine (or placebo). Cohort 2: n=28, volunteers will be randomly assigned to a single dose of either vaccine (10\^4 PFU, n=20) or placebo (n=8). All volunteers will be followed on an outpatient basis for 6 months following vaccination (13 follow up visits over 180 days). Follow up visits will include clinical assessments as well as sample collection for evaluation of viremia and seroconversion. Sample collection will include blood, urine, saliva, nasopharyngeal or midturbinate swab, vaginal secretion or semen collection on specified visit days throughout the 180 day follow up period.
Interventions
BIOLOGICALSingle dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml)
Administered at a dose of 10\^3 plaque-forming units (PFUs) by subcutaneous injection
BIOLOGICALSingle dose of placebo via subcutaneous injection (0.5ml).
Administered by subcutaneous injection.
BIOLOGICALSingle dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml)
Administered at a dose of using 10\^4 plaque-forming units (PFUs) by subcutaneous injection.
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Adult male or female between 18 and 50 years of age, inclusive. * Good general health as determined by physical examination, laboratory screening, and review of medical history. * Available for the duration of the study, which is approximately 26 weeks. * Willingness to participate in the study as evidenced by signing the informed consent document. * Females only: Female subjects of childbearing potential, with the exception noted below, should be willing to use effective contraception and have no plans to undergo IVF (in vitro fertilization) during participation in the trial. Reliable methods of contraception include hormonal birth control, condoms with spermicide, diaphragm with spermicide, surgical sterilization, and intrauterine device. Women must have been on an effective method of birth control for at least 30 days prior to enrollment. All female subjects will be considered as having childbearing potential, except for women who exclusively have sex with women, those who have had a hysterectomy, tubal ligation, or tubal coil (at least 3 months prior to vaccination), or are considered to be post-menopausal, as documented by at least 1 year since last menstrual period with a follicle-stimulating hormone (FSH) level in the menopausal range or at least 24 consecutive months of amenorrhea. Transgender men who have internal female organs and have sex with men will be considered of childbearing potential and should be willing to use effective contraception during the trial. Exception: Females who have sex with females (exclusively) and have no intention of conceiving a child during the study and women whose partners have had a vasectomy will not be required to use contraception, however they will be required to use female condoms and/or dental dams for at least 1 month following vaccination. For women whose sexual partner has had a vasectomy, the vasectomy must have been performed 30 days or more prior to enrollment. * Males only: Males of reproductive potential should be willing to use barrier contraception for the first 3 months following vaccination\* and agree to not donate sperm for the duration of the study. * Based on CDC guidance for men returning from ZIKV-endemic areas
Exclusion criteria
* Females only: Currently pregnant, as determined by positive β-human choriogonadotropin (HCG) test, or breast-feeding. * Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease based on history, physical examination, and/or laboratory studies. * Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the subject's ability to understand and cooperate with the requirements of the study protocol. * Screening laboratory values of Grade 1 or above for absolute neutrophil count (ANC), alanine aminotransferase (ALT), and serum creatinine, as defined in this protocol. * Any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a subject participating in the trial, or would render the subject unable to comply with the protocol. * Any significant alcohol or drug abuse in the past 12 months that has caused medical, occupational, or family problems, as indicated by subject history. * History of a severe allergic reaction or anaphylaxis. * Severe asthma (emergency room visit or hospitalization within the last 6 months). * HIV infection, as indicated by screening and confirmatory assays. * Hepatitis C virus (HCV) infection, as indicated by screening and confirmatory assays. * Hepatitis B virus (HBV) infection, as indicated by hepatitis B surface antigen (HBsAg) screening. * Any known immunodeficiency syndrome. * History of Guillain-Barrè syndrome. * Current use of anticoagulant medications (this does not include anti-platelet medication such as aspirin or non-steroidal anti-inflammatory medications). * Use of immunosuppressive corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 28 days prior to or following inoculation. An immunosuppressive dose of corticosteroids is defined as greater than or equal to 10 mg of a prednisone equivalent per day for greater than or equal to 14 days. * Receipt of a live vaccine within 28 days or a killed vaccine within 14 days prior to inoculation, or anticipated receipt of any vaccine during the 28 days following inoculation with the exception of COVID-19 vaccines either licensed or under EUA which can be given at any time, however all effort will be made to avoid giving COVID-19 vaccines within the above windows. * Asplenia. * Receipt of blood products within the past 6 months, including transfusions or immunoglobulin, or anticipated receipt of any blood products or immunoglobulin during the 28 days following inoculation. * History or serologic evidence of previous ZIKV or other flavivirus infection (e.g., dengue, yellow fever virus, St. Louis Encephalitis virus, or West Nile virus). * Previous receipt of a flavivirus vaccine (licensed or experimental). * Receipt or anticipated receipt of any investigational agent in the 28 days before or after inoculation with the exception of COVID-19 vaccines, either licensed or authorized under EUA. * Refusal to allow specimen storage for future research. * Is in isolation or quarantine for SARS-CoV-2 infection or exposure and cannot complete screening or enrollment for this reason.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Solicited Local and General Adverse Events (AEs) | Solicited AE's assessed every visit through Day 28 | Evaluated using the Adverse Event Grading Table in the study protocol. |
| To Determine the Immunogenicity of a Single Dose of rZIKV/D4Δ30-713 | Measured through Day 28 | Determination of the serum plaque reduction neutralization titer 50% (PRNT50) to ZIKV for each subject at Study Day 28 post-inoculation. Seroconversion will be defined as achieving a PRNT50 ≥ 1:10 at any time-point through Study Day 28. The peak PRNT50 to ZIKV through Study Day 28 will be calculated for each subject included in the per-protocol an intent-to-treat analysis and the geometric mean peak titer for vaccinated subjects will be calculated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity of rZIKV/D4Δ30-713 in Flavivirus-naïve Subjects | Measured through Day 180 | Evaluate the immunogenicity of rZIKV/D4Δ30-713 in flavivirus-naïve subjects as assessed by the PRNT50 to ZIKV, for each subject at Study Day 28, 56, and 90 post-administration of LA Zika vaccine. Expressed as geometric mean peak titer, reciprocal (median). Geometric mean titer was calculated at each time point for only those subjects with a titer of \>= 10, reciprocal. Seroconversion was defined as a PRNT(50) of \>= 10, reciprocal. |
| Viremia Induced by Vaccine (Number of Participants With Detectable Virus at Any Time Point) | Measured through Day 90 | Assess the frequency, quantity, and duration of viremia (virus in the blood) induced by a single dose of the rZIKV/D4Δ30-713 vaccine. The mean peak viremia, mean day of onset of viremia, and mean duration of viremia will be calculated. Viremia will be detected by culture (infectious virus) and by RT-PCR. |
| Quantity and Duration of ZIKV Presence | 90 days post vaccination | Determine the quantity and duration of ZIKV presence as determined by: * The peak virus titer in the blood and the duration of viremia induced by the LA Zika vaccine as determined by RT-PCR and virus culture * The quantity and duration of possible Zika vaccine shedding in urine determined by RT-PCR and virus culture * The quantity and duration of possible Zika vaccine shedding in vaginal secretions determined by RT-PCR and virus culture * The quantity and duration of possible Zika vaccine shedding in semen determined by RT-PCR and virus culture |
| Durability of Antibody Response | 26 Weeks post vaccination | Determine the durability of antibody response 26 weeks after vaccination. Neutralizing antibody titers to ZIKV were measured at 0, 28, 56, 90, 150, and 180 days following vaccination, with the peak neutralizing antibody titer determined as the peak titer in the 90 days following vaccination for either dose cohort. |
| Number of Vaccinees Infected With rZIKV/D4Δ30-713 | Measured through Day 180 | Determine the number of vaccinees infected with rZIKV/D4Δ30-713. Infection is defined as recovery of infectious vaccine virus from the blood, serum or urine of a subject and/or by seroconversion to ZIKV. Seroconversion will be defined as achieving a PRNT50 ≥ 1:10 by Study Day 90 post-vaccination. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1 - Vaccine rZIKV/D4Δ30-713 (10\^3 PFU) via subcutaneous injection (0.5ml). | 20 |
| Cohort 1 - Placebo Administered via subcutaneous injection (0.5ml). | 8 |
| Cohort 2 - Vaccine rZIKV/D4Δ30-713 (10\^4 PFU) via subcutaneous injection (0.5ml) | 20 |
| Cohort 2 - Placebo Administered via subcutaneous injection (0.5ml). | 8 |
| Total | 56 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Withdrawal by Subject | 0 | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | Cohort 1 - Vaccine | Cohort 1 - Placebo | Cohort 2 - Vaccine | Cohort 2 - Placebo | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 20 Participants | 8 Participants | 20 Participants | 8 Participants | 56 Participants |
| PRNT (50) ZIKV <= 10 | 20 Participants | 8 Participants | 20 Participants | 8 Participants | 56 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 0 Participants | 2 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants | 2 Participants | 3 Participants | 2 Participants | 11 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 14 Participants | 5 Participants | 14 Participants | 6 Participants | 39 Participants |
| Sex: Female, Male Female | 9 Participants | 5 Participants | 17 Participants | 6 Participants | 37 Participants |
| Sex: Female, Male Male | 11 Participants | 3 Participants | 3 Participants | 2 Participants | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 20 | 0 / 8 | 0 / 20 | 0 / 8 |
| other Total, other adverse events | 14 / 20 | 6 / 8 | 11 / 20 | 6 / 8 |
| serious Total, serious adverse events | 0 / 20 | 0 / 8 | 1 / 20 | 0 / 8 |
Outcome results
Primary
Number of Participants With Solicited Local and General Adverse Events (AEs)
Evaluated using the Adverse Event Grading Table in the study protocol.
Time frame: Solicited AE's assessed every visit through Day 28
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | elevated ALT | 0 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | retro-orbital pain (ROP) | 1 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | myalgia | 4 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | headache | 10 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | Injection Site Pruritus | 0 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | photophobia | 1 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | Thrombocytopenia | 0 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | Zika-like rash | 0 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | Injection Site Pain | 0 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | injection site erythema | 1 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | prolonged PT | 0 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | prolonged PTT | 0 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | Injection Site Induration | 0 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | muscle weakness | 1 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | arthralgia | 2 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | nausea | 4 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | Neutropenia | 0 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | fever | 0 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | fatigue | 5 Participants |
| Cohort 1 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | Injection Site Tenderness | 0 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | nausea | 2 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | Zika-like rash | 0 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | Injection Site Pain | 0 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | elevated ALT | 0 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | prolonged PT | 0 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | Neutropenia | 0 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | Thrombocytopenia | 0 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | myalgia | 2 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | prolonged PTT | 0 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | arthralgia | 1 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | Injection Site Pruritus | 0 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | retro-orbital pain (ROP) | 1 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | fatigue | 2 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | photophobia | 0 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | headache | 5 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | Injection Site Induration | 0 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | injection site erythema | 0 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | muscle weakness | 0 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | Injection Site Tenderness | 0 Participants |
| Cohort 1 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | fever | 0 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | prolonged PTT | 0 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | headache | 8 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | fatigue | 4 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | nausea | 2 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | myalgia | 3 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | arthralgia | 2 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | retro-orbital pain (ROP) | 0 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | photophobia | 1 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | injection site erythema | 1 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | muscle weakness | 0 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | fever | 1 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | Zika-like rash | 0 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | elevated ALT | 0 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | Neutropenia | 0 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | Thrombocytopenia | 0 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | Injection Site Pain | 0 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | Injection Site Tenderness | 0 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | Injection Site Induration | 0 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | Injection Site Pruritus | 0 Participants |
| Cohort 2 - Vaccine | Number of Participants With Solicited Local and General Adverse Events (AEs) | prolonged PT | 0 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | Injection Site Pain | 0 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | fever | 0 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | muscle weakness | 0 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | prolonged PT | 0 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | Injection Site Tenderness | 0 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | injection site erythema | 0 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | photophobia | 0 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | fatigue | 2 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | Injection Site Induration | 0 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | retro-orbital pain (ROP) | 2 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | arthralgia | 0 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | headache | 5 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | Injection Site Pruritus | 0 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | myalgia | 2 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | Neutropenia | 0 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | nausea | 2 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | Thrombocytopenia | 0 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | elevated ALT | 0 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | Zika-like rash | 0 Participants |
| Cohort 2 Placebo | Number of Participants With Solicited Local and General Adverse Events (AEs) | prolonged PTT | 0 Participants |
Primary
To Determine the Immunogenicity of a Single Dose of rZIKV/D4Δ30-713
Determination of the serum plaque reduction neutralization titer 50% (PRNT50) to ZIKV for each subject at Study Day 28 post-inoculation. Seroconversion will be defined as achieving a PRNT50 ≥ 1:10 at any time-point through Study Day 28. The peak PRNT50 to ZIKV through Study Day 28 will be calculated for each subject included in the per-protocol an intent-to-treat analysis and the geometric mean peak titer for vaccinated subjects will be calculated.
Time frame: Measured through Day 28
Population: Note titer is not available under measure type option. Therefore we went with the best-fitting answer of number.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Cohort 1 - Vaccine | To Determine the Immunogenicity of a Single Dose of rZIKV/D4Δ30-713 | 56.1 PRNT(50) Titer |
| Cohort 1 Placebo | To Determine the Immunogenicity of a Single Dose of rZIKV/D4Δ30-713 | 126.1 PRNT(50) Titer |
Secondary
Durability of Antibody Response
Determine the durability of antibody response 26 weeks after vaccination. Neutralizing antibody titers to ZIKV were measured at 0, 28, 56, 90, 150, and 180 days following vaccination, with the peak neutralizing antibody titer determined as the peak titer in the 90 days following vaccination for either dose cohort.
Time frame: 26 Weeks post vaccination
Population: Analysis that is applicable only to post-vaccine (not placebo) subjects.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Cohort 1 - Vaccine | Durability of Antibody Response | 56.1 titer |
| Cohort 2 - Vaccine | Durability of Antibody Response | 126.1 titer |
Secondary
Immunogenicity of rZIKV/D4Δ30-713 in Flavivirus-naïve Subjects
Evaluate the immunogenicity of rZIKV/D4Δ30-713 in flavivirus-naïve subjects as assessed by the PRNT50 to ZIKV, for each subject at Study Day 28, 56, and 90 post-administration of LA Zika vaccine. Expressed as geometric mean peak titer, reciprocal (median). Geometric mean titer was calculated at each time point for only those subjects with a titer of \>= 10, reciprocal. Seroconversion was defined as a PRNT(50) of \>= 10, reciprocal.
Time frame: Measured through Day 180
Population: Analysis that is applicable only to post-vaccine (not placebo) subjects.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Cohort 1 - Vaccine | Immunogenicity of rZIKV/D4Δ30-713 in Flavivirus-naïve Subjects | 56.1 titer |
| Cohort 2 - Vaccine | Immunogenicity of rZIKV/D4Δ30-713 in Flavivirus-naïve Subjects | 126.1 titer |
Secondary
Number of Vaccinees Infected With rZIKV/D4Δ30-713
Determine the number of vaccinees infected with rZIKV/D4Δ30-713. Infection is defined as recovery of infectious vaccine virus from the blood, serum or urine of a subject and/or by seroconversion to ZIKV. Seroconversion will be defined as achieving a PRNT50 ≥ 1:10 by Study Day 90 post-vaccination.
Time frame: Measured through Day 180
Population: Analysis that is applicable only to post-vaccine (not placebo) subjects.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1 - Vaccine | Number of Vaccinees Infected With rZIKV/D4Δ30-713 | 9 #participants who seroconverted |
| Cohort 2 - Vaccine | Number of Vaccinees Infected With rZIKV/D4Δ30-713 | 7 #participants who seroconverted |
Secondary
Quantity and Duration of ZIKV Presence
Determine the quantity and duration of ZIKV presence as determined by: * The peak virus titer in the blood and the duration of viremia induced by the LA Zika vaccine as determined by RT-PCR and virus culture * The quantity and duration of possible Zika vaccine shedding in urine determined by RT-PCR and virus culture * The quantity and duration of possible Zika vaccine shedding in vaginal secretions determined by RT-PCR and virus culture * The quantity and duration of possible Zika vaccine shedding in semen determined by RT-PCR and virus culture
Time frame: 90 days post vaccination
Population: Number of participants with recovered ZIKV from any bodily fluid (serum, urine, semen, and cervico-vaginal secretions) at any time point post-vaccination, as assessed by PCR and culture.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort 1 - Vaccine | Quantity and Duration of ZIKV Presence | Recovered vaccine virus from serum at any time point post-vaccination as assessed by PCR and culture | 0 Number of participants |
| Cohort 1 - Vaccine | Quantity and Duration of ZIKV Presence | Recovered vaccine virus from urine at any time point post-vaccination as assessed by PCR and culture | 0 Number of participants |
| Cohort 1 - Vaccine | Quantity and Duration of ZIKV Presence | Recovered vaccine virus from semen at any time point post-vaccination as assessed by PCR and culture | 0 Number of participants |
| Cohort 1 - Vaccine | Quantity and Duration of ZIKV Presence | Recovered vaccine virus from CVS at any time point post-vaccination as assessed by PCR and culture | 0 Number of participants |
| Cohort 1 Placebo | Quantity and Duration of ZIKV Presence | Recovered vaccine virus from urine at any time point post-vaccination as assessed by PCR and culture | 0 Number of participants |
| Cohort 1 Placebo | Quantity and Duration of ZIKV Presence | Recovered vaccine virus from CVS at any time point post-vaccination as assessed by PCR and culture | 0 Number of participants |
| Cohort 1 Placebo | Quantity and Duration of ZIKV Presence | Recovered vaccine virus from serum at any time point post-vaccination as assessed by PCR and culture | 0 Number of participants |
| Cohort 1 Placebo | Quantity and Duration of ZIKV Presence | Recovered vaccine virus from semen at any time point post-vaccination as assessed by PCR and culture | 0 Number of participants |
| Cohort 2 - Vaccine | Quantity and Duration of ZIKV Presence | Recovered vaccine virus from serum at any time point post-vaccination as assessed by PCR and culture | 0 Number of participants |
| Cohort 2 - Vaccine | Quantity and Duration of ZIKV Presence | Recovered vaccine virus from CVS at any time point post-vaccination as assessed by PCR and culture | 0 Number of participants |
| Cohort 2 - Vaccine | Quantity and Duration of ZIKV Presence | Recovered vaccine virus from semen at any time point post-vaccination as assessed by PCR and culture | 0 Number of participants |
| Cohort 2 - Vaccine | Quantity and Duration of ZIKV Presence | Recovered vaccine virus from urine at any time point post-vaccination as assessed by PCR and culture | 0 Number of participants |
| Cohort 2 Placebo | Quantity and Duration of ZIKV Presence | Recovered vaccine virus from CVS at any time point post-vaccination as assessed by PCR and culture | 0 Number of participants |
| Cohort 2 Placebo | Quantity and Duration of ZIKV Presence | Recovered vaccine virus from serum at any time point post-vaccination as assessed by PCR and culture | 0 Number of participants |
| Cohort 2 Placebo | Quantity and Duration of ZIKV Presence | Recovered vaccine virus from urine at any time point post-vaccination as assessed by PCR and culture | 0 Number of participants |
| Cohort 2 Placebo | Quantity and Duration of ZIKV Presence | Recovered vaccine virus from semen at any time point post-vaccination as assessed by PCR and culture | 0 Number of participants |
Secondary
Viremia Induced by Vaccine (Number of Participants With Detectable Virus at Any Time Point)
Assess the frequency, quantity, and duration of viremia (virus in the blood) induced by a single dose of the rZIKV/D4Δ30-713 vaccine. The mean peak viremia, mean day of onset of viremia, and mean duration of viremia will be calculated. Viremia will be detected by culture (infectious virus) and by RT-PCR.
Time frame: Measured through Day 90
Population: Analysis that is applicable only to post-vaccine (not placebo) subjects.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1 - Vaccine | Viremia Induced by Vaccine (Number of Participants With Detectable Virus at Any Time Point) | 0 #participants w/ vaccine-induced viremia |
| Cohort 2 - Vaccine | Viremia Induced by Vaccine (Number of Participants With Detectable Virus at Any Time Point) | 0 #participants w/ vaccine-induced viremia |